Catalyst Event
Biocytogen Pharmaceuticals (Beijing) Co Ltd (2315) · Earnings Release
From Akros SCHK HK-Global Genomics Index (ASHGGENM)
4/27/2026, 12:00:00 AM
Biocytogen released its first-quarter 2026 report on 2026-04-27, showing revenue of about RMB 433.1 million and net profit attributable to shareholders of about RMB 104.0 million versus a loss a year earlier; likely medium positive due to the clear quarterly turnaround.
Korean Translation
2026-04-27 2026년 1분기 실적 발표로 매출 약 4.331억위안, 지배주주순이익 약 1.040억위안 기록하며 전년 동기 적자에서 흑자전환함.
Related Recent Events
WuXi Biologics (Cayman) Inc (2269) · Other
The U.S. Office of Management and Budget (OMB) is scheduled to publish a full list of 'biotechnology companies of concern' (BCCs) by December 18, 2026, under the BIOSECURE Act; High importance is justified by the potential for severe regulatory risk causing a >10% price impact scheduled.
12/18/2026, 12:00:00 AM
Livzon Pharmaceutical Group Inc (1513) · Other
Ex-dividend date on June 16, 2026, for the 2025 final cash dividend of RMB 14.3 per 10 shares, with payment on July 13, 2026, scheduled. This consistent dividend payout is estimated to have a minor positive impact on investor sentiment.
6/16/2026, 12:00:00 AM
Grand Pharmaceutical Group Ltd (512) · Other
Ex-dividend date for a proposed final dividend of HK$0.169 per share for the year ended December 31, 2025, on 2026-06-12 scheduled. Low importance as dividend ex-dates typically result in minor price adjustments.
6/12/2026, 12:00:00 AM
Hangzhou Tigermed Consulting Co Ltd (3347) · Other
Annual General Meeting scheduled for June 2, 2026, to vote on the 2025 profit distribution plan, a final dividend of RMB 1.26 per 10 shares, and a general mandate for the board to repurchase H-shares. Routine AGM and dividend announcement are likely to cause a price impact of 1% or more, scheduled.
6/2/2026, 12:00:00 AM
GRAIL Inc (GRAL) · Other
GRAIL to present additional data from the NHS-Galleri trial at the 2026 ASCO Annual Meeting on May 30, 2026, scheduled. High importance estimated as clinical data is a key valuation driver.
5/30/2026, 12:00:00 AM
ANTA Sports Products Limited (2020) · Other
Ex-dividend date for the final FY2025 dividend of HK$1.08 per share is scheduled for May 15, 2026.
5/15/2026, 12:00:00 AM